Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 3:9:978.
doi: 10.3389/fimmu.2018.00978. eCollection 2018.

Targeting VEGF/VEGFR to Modulate Antitumor Immunity

Ju Yang  1 , Jing Yan  1 , Baorui Liu  1
Affiliations
Review

Targeting VEGF/VEGFR to Modulate Antitumor Immunity

Ju Yang et al. Front Immunol. .

Abstract

In addition to the crucial role in promoting the growth of tumor vessels, vascular endothelial growth factor (VEGF) is also immunosuppressive. VEGF can inhibit the function of T cells, increase the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and hinder the differentiation and activation of dendritic cells (DCs). Recent studies have investigated the role of antiangiogenic agents in antitumor immunity, especially in recent 3 years. Therefore, it is necessary to update the role of targeting VEGF/VEGFR in antitumor immunity. In this review, we focus on the latest clinical and preclinical findings on the modulatory role of antiangiogenic agents targeting VEGF/VEGFR in immune cells, including effector T cells, Tregs, MDSCs, DCs, tumor-associated macrophages, and mast cells. Our review will be potentially helpful for the development of combinations of angiogenesis inhibitors with immunological modulators.

Keywords: T cells; angiogenesis; immune; tumor; vascular endothelial growth factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of vascular endothelial growth factor (VEGF) on T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSC), and dendritic cell (DC).
See this image and copyright information in PMC

References

    1. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 27:563–84. 10.1146/annurev-cellbio-092910-154002 - DOI - PubMed
    1. Sia D, Alsinet C, Newell P, Villanueva A. VEGF signaling in cancer treatment. Curr Pharm Des (2014) 20:2834–42. 10.2174/13816128113199990590 - DOI - PubMed
    1. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer (2008) 8:604–17. 10.1038/nrc2353 - DOI - PMC - PubMed
    1. Wang J, Chen J, Guo Y, Wang B, Chu H. Strategies targeting angiogenesis in advanced non-small cell lung cancer. Oncotarget (2017) 8:53854–72. 10.18632/oncotarget.17957 - DOI - PMC - PubMed
    1. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol (2016) 17:611–25. 10.1038/nrm.2016.87 - DOI - PubMed

Publication types

MeSH terms

Substances